Acyclic nucleosides as antiviral compounds
Authors:
- 1 April 1996
- journal article
- review article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 5 (2) , 125-137
Abstract
Acyclovir is an effective drug for the treatment of HSV and VZV infections, which after phosphorylation to the triphosphate, inhibits viral DNA polymerase. Acyclovir has low oral bioavailability, therefore prodrugs have been developed, and the L-valyl ester, valaciclovir, recently has been licensed for the treatment of shingles. Ganciclovir is used against CMV, and famciclovir, a lipophilic prodrug of penciclovir, is marketed for shingles. The acyclic nucleoside phosphonates are active against thymidine kinase-resistant viral strains. Promising analogs are PMEA (in clinical trial for the treatment of AIDS) and (S)- HPMPC (good in vivo activity against HSV, VZV, CMV, and EBV). Oligonucleotides incorporating acyclic nucleosides at the 3’t and 5’t-ends, or constituted of amino acyclic nucleosides, are resistant to cleavage by nucleases and may be useful in antisense and/or antigene therapy. HEPT is active against HIV-1: It binds in a hydrophobic pocket on reverse transcriptase, rather than in the polymerase active site. Some acyclic nucleosides are potent inhibitors of purine and pyrimidine nucleoside phosphorylase. These compounds may have a therapeutic niche in combination therapy with antiviral and anticancer nucleosides, and in the treatment of diseases involving the T-cell.Keywords
This publication has 93 references indexed in Scilit:
- Pharmacokinetics of New Antiherpetic AgentsClinical Pharmacokinetics, 1995
- Recognition and Treatment of ShinglesDrugs, 1994
- GanciclovirDrugs, 1994
- Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivativesPharmacy World & Science, 1994
- Genital HerpesDrugs, 1994
- AciclovirDrugs, 1994
- Use of isotopically chiral [4′‐13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV‐1‐ and HSV‐2‐infected cells and by HSV‐1‐encoded thymidine kinaseChirality, 1993
- The acyclovir legacy: Its contribution to antiviral drug discoveryJournal of Medical Virology, 1993
- Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytesBiochemical and Biophysical Research Communications, 1991
- Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivativeBiochemical and Biophysical Research Communications, 1989